Jennifer A. Lockridge
Novo Nordisk (Denmark)(DK)Novo Nordisk (United States)(US)
Publications by Year
Research Areas
RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques, MicroRNA in disease regulation, Hepatitis B Virus Studies, Cancer-related molecular mechanisms research
Most-Cited Works
- → Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs(2005)1,161 cited
- → Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†(2005)290 cited
- → Virally delivered Channelrhodopsin-2 Safely and Effectively Restores Visual Function in Multiple Mouse Models of Blindness(2011)275 cited
- → RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027(2010)188 cited
- → A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors(2005)75 cited
- → Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex(2006)54 cited
- → Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors(2005)44 cited
- → Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy(2017)41 cited
- → Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics(2017)32 cited
- → Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices(2003)14 cited